Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100

In the DEVOTE and SWITCH 2 trials, insulin degludec 100 units/mL (degludec) was superior to insulin glargine 100 units/mL (glargine U100) with respect to the rates of severe (DEVOTE; across trial) and overall symptomatic (SWITCH 2; during the maintenance period of the trial) hypoglycaemia in individ...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Alexopoulos, Anastasia‐Stefania, Andersen, Andreas, Donatsky, Anders Meller, Gowda, Amoolya, Buse, John B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2021
Soggetti:
Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8286333/
https://ncbi.nlm.nih.gov/pubmed/33830626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.14397
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi